Interstitial Lung Disease clinical trials at UC Davis

5 in progress, 2 open to eligible people

Showing trials for

  • Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

    open to eligible people ages 18 years and up

    Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

    Sacramento, California and other locations

  • ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

    open to eligible people ages 18 years and up

    This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

    Rancho Cordova, California and other locations

  • Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

    Sorry, accepting new patients by invitation only

    Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

    Sacramento, California and other locations

  • Mosliciguat in PH-ILD

    Sorry, in progress, not accepting new patients

    This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

    Sacramento, California and other locations

  • Dry Powder Inhaled Treprostinil in PH

    Sorry, not currently recruiting here

    Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.

    Sacremento, California and other locations

Our lead scientists for Interstitial Lung Disease research studies include .

Last updated: